Alice Melão, MSc,  —

Articles by Alice Melao

Promedior and Its Potential IPF Treatment, PRM-151, Acquired by Roche

Roche has acquired Promedior, a biotechnology company, and its full portfolio of molecules to possibly treat fibrotic diseases. The portfolio includes PRM-151, a lead therapy candidate for  idiopathic pulmonary fibrosis (IPF) advancing in clinical testing. PRM-151 is a synthetic engineered version of pentraxin-2, a protein that is able to…

Processa Pharmaceuticals Will Evaluate HT-100 as Treatment for IPF, Other Fibrotic Diseases

Processa Pharmaceuticals will explore and further develop the anti-fibrotic, anti-inflammatory compound HT-100 as a potential treatment for rare fibrotic-related diseases in adults, including focal segmental glomerulosclerosis, scleroderma, and idiopathic pulmonary fibrosis (IPF). The company announced that it has acquired the exclusive global rights to develop…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums